Aquestive Therapeutics (AQST) Awaits Anaphylm NDA Approval in Q3

Core Viewpoint - Aquestive Therapeutics Inc. is recognized as one of the top small-cap drug manufacturing stocks to consider for investment, despite a recent reduction in its price target by Alliance Global from $12 to $9 while maintaining a Buy rating [1][2]. Financial Performance - The company reported fourth-quarter revenue of $13.02 million, which fell short of consensus estimates of $13.28 million [3]. - The CEO emphasized the company's readiness to advance Anaphylm, the first oral epinephrine rescue medication, towards FDA approval by 2026 [3]. Pipeline and Product Development - The company is focused on addressing deficiencies identified by the FDA in its Complete Response Letter, with plans for NDA resubmission for Anaphylm in Q3 2026 [1][4]. - The commercial infrastructure is deemed intact and adaptable to the new timeline, with a growing allergy market and strong patient preference for Anaphylm [4]. - The company’s product offerings include Libervant, Suboxone, EMYLIF, ONDIF, SYMPAZAN, KYNMOBI, and AZSTARYS, along with proprietary pipeline items Anaphylm and AQST-108 [5]. Valuation Insights - Alliance Global provided a detailed valuation of the company's pipeline and assets, including contributions from Anaphylm and Libervant, which supports their updated view on the shares [2].